Tetra Collaborates with Cellvera to Develop a Potential Oral Combination Treatment for COVID-19 Patients

Tetra Bio-Pharma, Inc. announced that they signed an agreement with Cellvera Global Holdings LLC for the co-development of ARDS-003 as a combination product with Qifenda 400MG, a commercial-stage broad-spectrum antiviral drug.